NASDAQ:WINT Windtree Therapeutics (WINT) Stock Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free WINT Stock Alerts $0.34 -0.06 (-15.01%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$0.27▼$0.4150-Day Range$0.31▼$0.4452-Week Range$0.27▼$7.79Volume1.79 million shsAverage Volume280,849 shsMarket Capitalization$1.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Windtree Therapeutics alerts: Email Address Windtree Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.39) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.42 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Windtree Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.54% of the float of Windtree Therapeutics has been sold short.Short Interest Ratio / Days to CoverWindtree Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Windtree Therapeutics has recently increased by 30.16%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldWindtree Therapeutics does not currently pay a dividend.Dividend GrowthWindtree Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for WINT. Previous Next 2.7 News and Social Media Coverage News SentimentWindtree Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Windtree Therapeutics this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Windtree Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.54% of the stock of Windtree Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.33% of the stock of Windtree Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Windtree Therapeutics are expected to grow in the coming year, from ($1.39) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Windtree Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Windtree Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWindtree Therapeutics has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About Windtree Therapeutics Stock (NASDAQ:WINT)Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics, Inc. has a scientific collaboration with Chang Gung University for cardiovascular diseases of SERCA2a; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.Read More WINT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WINT Stock News HeadlinesApril 18, 2024 | msn.comWhy Windtree Therapeutics (WINT) Stock Is Getting HammeredApril 18, 2024 | globenewswire.comWindtree Therapeutics Announces Reverse Stock SplitApril 18, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereApril 17, 2024 | finance.yahoo.comWindtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business UpdatesApril 17, 2024 | globenewswire.comWindtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business UpdatesApril 13, 2024 | americanbankingnews.comWindtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Growth in Short InterestApril 9, 2024 | finanznachrichten.deWindtree Therapeutics: Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge FinancingApril 8, 2024 | globenewswire.comWindtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge FinancingApril 18, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereFebruary 2, 2024 | msn.comWindtree Therapeutics Seeks Strategic Alternatives with Ladenburg ThalmannFebruary 1, 2024 | finance.yahoo.comWindtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a ResearchJanuary 31, 2024 | bizjournals.comWindtree Therapeutics hires investment bank to explore M&A optionsJanuary 31, 2024 | finance.yahoo.comWindtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic AlternativesJanuary 29, 2024 | benzinga.comWindtree Therapeutics – This Biotech Inks License Deal For Lead CandidateJanuary 26, 2024 | finanznachrichten.deWindtree Therapeutics Eliminates $15 Million Contingent Liability To Deerfield Management CompanyJanuary 26, 2024 | finance.yahoo.comWindtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management CompanyJanuary 25, 2024 | benzinga.comWindtree Therapeutics (NASDAQ: WINT) Eliminates $15 Million Contingent Liability To Deerfield Management CompanyJanuary 25, 2024 | finance.yahoo.comWindtree Eliminates $15 Million Contingent Liability to Deerfield Management CompanyJanuary 24, 2024 | money.usnews.comWindtree Therapeutics IncJanuary 18, 2024 | msn.comWindtree and Lee’s sign licence deal for heart failure therapyJanuary 18, 2024 | finance.yahoo.comUp To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater ChinaJanuary 17, 2024 | bizjournals.comWindtree Therapeutics signs drug licensing deal valued at up to $138M with Chinese drug companyJanuary 17, 2024 | finance.yahoo.comWindtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific RegionJanuary 4, 2024 | markets.businessinsider.comHold Rating on Windtree Therapeutics Pending Key Istaroxime StudiesJanuary 3, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Windtree Therapeutics (WINT) with Neutral RecommendationJanuary 2, 2024 | markets.businessinsider.comWindtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a ActivatorJanuary 2, 2024 | finance.yahoo.comWindtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a ActivatorSee More Headlines Receive WINT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/03/2023Today4/18/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:WINT CUSIPN/A CIK946486 Webwww.windtreetx.com Phone(215) 488-9300Fax215-488-9301Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($8.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-274.89% Return on Assets-66.31% Debt Debt-to-Equity Ratio2.00 Current Ratio2.40 Quick Ratio2.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.97 per share Price / Book0.02Miscellaneous Outstanding Shares5,150,000Free Float5,120,000Market Cap$1.44 million OptionableNot Optionable Beta0.61 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Craig E. Fraser (Age 59)Chairman, President, CEO & Interim Principal Officer Comp: $553.75kDr. Steven G. Simonson (Age 65)Senior VP & Chief Medical Officer Comp: $446.1kMr. Eric L. Curtis M.B.A. (Age 56)Senior VP & COO Comp: $526.25kMs. Jamie McAndrew (Age 43)VP, Controller, Chief Accounting Officer & Corporate Secretary Mr. George Cox (Age 72)Vice President of Technical Operations Dr. Pratap ParuchuruExecutive Director of Clinical DevelopmentMs. Tracy RarickHead of Operations & Program ManagementMore ExecutivesKey CompetitorsGamida CellNASDAQ:GMDAGamida CellNASDAQ:GMDAQSQZ BiotechnologiesNYSE:SQZEloxx PharmaceuticalsNASDAQ:ELOXTC BiopharmNASDAQ:TCBPView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 38,877 shares on 2/26/2024Ownership: 0.755%Citadel Advisors LLCBought 38,128 shares on 2/15/2024Ownership: 0.741%Craig FraserBought 2,500 shares on 9/26/2023Total: $2,250.00 ($0.90/share)Craig FraserBought 1,315 shares on 4/25/2023Total: $2,485.35 ($1.89/share)View All Insider TransactionsView All Institutional Transactions WINT Stock Analysis - Frequently Asked Questions Should I buy or sell Windtree Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Windtree Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WINT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WINT, but not buy additional shares or sell existing shares. View WINT analyst ratings or view top-rated stocks. How have WINT shares performed in 2024? Windtree Therapeutics' stock was trading at $0.7190 at the beginning of the year. Since then, WINT shares have decreased by 49.4% and is now trading at $0.3638. View the best growth stocks for 2024 here. Are investors shorting Windtree Therapeutics? Windtree Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 39,700 shares, an increase of 30.2% from the March 15th total of 30,500 shares. Based on an average trading volume of 249,600 shares, the short-interest ratio is presently 0.2 days. Approximately 0.5% of the shares of the stock are short sold. View Windtree Therapeutics' Short Interest. When is Windtree Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our WINT earnings forecast. How were Windtree Therapeutics' earnings last quarter? Windtree Therapeutics, Inc. (NASDAQ:WINT) announced its earnings results on Monday, April, 3rd. The company reported ($13.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($10.50) by $2.51. When did Windtree Therapeutics' stock split? Shares of Windtree Therapeutics reverse split on Thursday, February 23rd 2023. The 1-50 reverse split was announced on Thursday, February 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Windtree Therapeutics? Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:WINT) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressThe “Perfect Storm” for GoldGold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.